Treatment of SLE with anti-CD19 CAR-T cellsdoi:10.1038/s41581-022-00651-3Ellen F. CarneyNature Reviews NephrologyNature Publishing Group UKNature Reviews Nephrology
With this in mind, in the last decade, many efforts have been made to use other treatments for cancer in combination with tuberculosis to increase the effectiveness of CAR-T cell therapy, especially in solid tumors. The combination therapy results have promising consequences for tumor regression an...
& Sanz, I. Treatment of SLE with anti-CD20 monoclonal antibody. Curr. Dir. Autoimmun. 8, 193–205 (2005). Article CAS PubMed Google Scholar Keystone, E. C. B cells in rheumatoid arthritis: from hypothesis to the clinic. Rheumatology (Oxford) 44, (Suppl. 2), ii8–ii12 (2005). ...
Approaches for the development of therapeutic antibodies.aThe traditional mouse hybridoma technique starts by immunization of mice with desired antigens to trigger an immune response. Harvested splenocytes are fused with myeloma cells to produce hybridoma cells that persistently secrete antibodies. After ...
Though the field of cell therapy is relatively new, as an industry we have packed incredible progress into the last two decades; from the first effective CAR T cells developed by researchers in 2002 to six FDA-approved cell therapies for blood cancers now on the market, with the...
The emerging therapeutic approach of CAR-T cell therapy has sparked great interests, extensive studies in preclinical and clinical trials have revealed encouraging therapeutic efficacy in treating a variety of cancers, particularly in treating B-cell hematologic malignancies with CD19 CAR-T cells [3]....
The invention provides methods of treating autoimmune diseases using lower doses of anti-CD20 antibodies effective to deplete B cells in the patient.
cells. IASO-782 has the potential to treat a range of autoimmune diseases associated with auto-reactive antibodies. As IASO-782 is a fully human antibody, it has potentially low immunogenicity and is less likely to induce anti-drug antibodies after repeated administration. This provides a ...
“Recent studies have shown that CD19 targeted cell therapies can make a meaningful impact on non-renal SLE, LN and other autoimmune conditions,” said Naiyer Rizvi, M.D., chief medical officer of Synthekine. “However, successful treatment with CD19 CAR-Ts requires patients to be lymphodepl...
(EBV)-sensitized T cells that express a second generation CD19 CAR construct for the treatment of CD19+ relapsed or refractory B-cell malignancies, including B-cell non-Hodgkin’s lymphoma and B-cell mediated autoimmune diseases including systemic lupus erythematosus (SLE) with kidney involvement ...